Kurse werden geladen...
Prognose
Für dieses Unternehmen liegen uns keine Analysten-Daten vor.
Scoring-Modelle
Dividenden-Strategie | 3 / 15 |
HGI-Strategie | 8 / 18 |
Levermann-Strategie | 4 / 13 |
Beliebteste Broker
News
- 27.08. - 14:00 Uhr
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / August 27, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that the country of Jordan's Industrial Property Protection Directorate has issued a new patent to Jaguar family company Napo Pharmaceuticals (Napo) for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar's novel plant-based prescription drug. "We are very pleased that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS," said Lisa Conte, Jaguar's founder, president, and CEO. » Mehr auf accesswire.com
- 19.08. - 14:00 Uhr
Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Hong Kong's Intellectual Property Department has issued a new patent to Jaguar family company Napo Pharmaceuticals for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar's novel plant-based prescription drug. "We are very happy that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS," said Lisa Conte, Jaguar's founder, president, and CEO. » Mehr auf accesswire.com
- 19.08. - 13:50 Uhr
Here's Why Momentum in Sabesp (SBS) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Sabesp (SBS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. » Mehr auf zacks.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | Juni 2024 | |
---|---|---|
Umsatz | 1,12 Mrd | 4,50% |
Bruttoeinkommen | 471,50 Mio | 26,83% |
Nettoeinkommen | 201,43 Mio | 41,61% |
EBITDA | 497,87 Mio | 77,44% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 10,79 Mrd € |
Anzahl Aktien | 683,51 Mio |
52 Wochen-Hoch/Tief | 16,50 € - 10,15 € |
Dividendenrendite | 1,65 % |
Dividenden TTM | 0,26 € |
Beta | 0,53 |
KGV (PE Ratio) | 16,19 |
KGWV (PEG Ratio) | 1,72 |
KBV (PB Ratio) | 2,07 |
KUV (PS Ratio) | 2,43 |
Unternehmensprofil
Die Companhia de Saneamento Básico do Estado de São Paulo - SABESP erbringt Wasser- und Abwasserdienstleistungen für private, gewerbliche, industrielle und staatliche Kunden. Das Unternehmen erbringt Dienstleistungen in den Bereichen Wasserversorgung, Abwasserentsorgung, Regenwasserbewirtschaftung und -ableitung, Stadtreinigung und Abfallentsorgung sowie damit verbundene Tätigkeiten, einschließlich Planung, Betrieb, Wartung und Vermarktung von Energie. Zum 31. Dezember 2021 versorgte das Unternehmen ca. 27,8 Millionen Menschen mit 9,8 Millionen Wasseranschlüssen, ca. 24,6 Millionen Menschen mit 8,4 Millionen Abwasseranschlüssen und betrieb 88.904 Kilometer Wasser- und Wassertransportleitungen sowie 61.122 Kilometer Kanalisationsleitungen. Darüber hinaus bietet das Unternehmen über Zweckgesellschaften Wasser- und/oder Abwasserdienstleistungen für vier weitere Gemeinden an. Das Unternehmen wurde 1954 gegründet und hat seinen Hauptsitz in São Paulo, Brasilien.
Name | Sabesp ADR |
CEO | Andre Gustavo Salcedo Teixeira Mendes |
Sitz | São Paulo,
sp Brasilien |
Website | |
Industrie | Wasserversorgungsunternehmen |
Börsengang | 10.05.2002 |
Mitarbeiter | 10.158 |
Ticker Symbole
Börse | Symbol |
---|---|
NYSE | SBS |
Frankfurt | SAJA.F |
München | SAJA.MU |
Düsseldorf | SAJA.DU |
Assets entdecken
Shareholder von Sabesp ADR investieren auch in folgende Assets